Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma, A Phase II Study

NCT00293319 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT00293319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00293319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma, A Phase II Study
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
March 31, 2006
Enrollment
164 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma